Cofertility vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cofertility matches women who want to freeze eggs for their future with intended parents who need donor eggs, reducing the cost of freezing by sharing eggs with recipients.
About
Cofertility is a fertility technology company founded in 2021 that has created a unique egg sharing model connecting women who want to freeze their eggs with intended parents who need donor eggs. Through the platform's Split program, egg donors freeze half of their eggs for their own future use while the other half goes to recipients, with the recipient paying for the donor's entire egg freezing cycle. This arrangement makes egg freezing free for donors who would otherwise pay $10,000 or more out of pocket, while providing recipients with a younger, more diverse egg donor pool. Cofertility raised $30M and has built the largest technology-first egg donation platform, emphasizing donor safety, informed consent, and transparent compensation practices that differ from traditional egg donation agencies. The company screens donors and handles all clinical coordination with partner fertility clinics. Cofertility addresses both the financial barrier to egg freezing that prevents many women from accessing this preventive care and the limited supply of diverse egg donors that many intended parents face. The platform represents a novel market structure that creates value for donors, recipients, and the overall fertility ecosystem simultaneously.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.